Graft-versus-host disease cost-effectiveness of therapy: Difference between revisions
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Graft-versus-host disease}} | {{Graft-versus-host disease}} | ||
{{CMG}} | {{CMG}} {{shyam}} | ||
==Overview== | ==Overview== |
Revision as of 20:32, 22 June 2017
Graft-versus-host disease |
Differentiating Graft-versus-host disease from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Graft-versus-host disease cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Graft-versus-host disease cost-effectiveness of therapy |
FDA on Graft-versus-host disease cost-effectiveness of therapy |
CDC on Graft-versus-host disease cost-effectiveness of therapy |
Graft-versus-host disease cost-effectiveness of therapy in the news |
Blogs on Graft-versus-host disease cost-effectiveness of therapy |
Risk calculators and risk factors for Graft-versus-host disease cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Cost-Effectiveness of Therapy
Corticosteroids are the most cost-effective therapy for GvHD. Prednisone and methylprednisolone are available at very low cost. Second-line therapies and cell-based therapies are significantly more expensive. If corticosteroids can be used, these should be given first.